

, \* , \*\*

. \* . \*\* . \*\* .

**A Case of Pregnancy Using Recombinant Follicle Stimulating Hormone and Gonadotropin Releasing Hormone Antagonist**

**Yoon Sung Nam, Nam Keun Kim\*, Eun Kyung Kim\*\*,  
Hyung Min Chung\*\* and Kwang Yul Cha**

Department of Obstetrics and Gynecology,  
Department of Genetics,\* Department of Embryology,\*\*  
College of Medicine, Pocheon CHA University, Pocheon, Korea

**Objective** : To report the pregnancy which was made by in vitro fertilization using recombinant follicle stimulating hormone and gonadotropin releasing hormone antagonist.

**Material and Method** : Case report.

**Results** : Six oocytes were retrieved and all were fertilized by intracytoplasmic sperm injection. Six embryos were transferred and the pregnancy was confirmed.

**Conclusions** : It is envisaged that the availability of recombinant gonadotropins and gonadotropin releasing hormone antagonists will ultimately lead to shorter, cheaper and safer treatments, using reduced dosages.

---

**Key Words** : Recombinant follicle stimulating hormone,

Gonadotropin releasing hormone antagonist

1980

1990  
가 가

GnRH) (antagonist) (gonadotropin releasing hormone :

가

(agonist)

가

mg  
17

Cetrorelix 3  
6 -

12

162cm, 51kg, 가 120 / 80 mmHg, 36.5°C, 80 /

가

: 0.7 x 10<sup>6</sup>/mL, : 42%, : 4%

11

가

11

가

6

3

가

5 ( 3 7 ) Gonol - F 225 IU  
4 8 10 Cetrotide 0.25 mg

hCG

3.18 mIU/mL, 6.10 mIU/mL

0.97 ng/mL, 1.90 ng/mL

6


6

12

hCG 가 487.7 mIU/mL

(recombinant follicle stimulating hormone)  
(urinary follicle stimulating hormone)

1-2



10

가

Gonal – F Puregon

11

가  
(antagonist)

가

12-13 cetorelix ganirelix

6

( 7 )  
14-15

hCG  
cetorelix ganirelix 0.25 mg

7 – 8 cetorelix 3 mg

3

가

11 – 12 cetorelix 0.25 mg 가

16

17

1 –

2

가

가

가

(granulosa cell),

18

ganirelix 가

가 .

가 .

가 .

가 .

(follicular synchrony) 가 .

가 .

가 .

가 .

가 .

가 .

가 .

hCG 가 .

hCG .

19 .

20 .

가 .

가 .

1. Out HJ, Mannerts BMJL, Driessen SGAJ, Coeling Bennick HJT.

- A prospective, randomised, assessor – blind, multicenter study comparing recombinant and urinary follicle stimulating hormone(Puregon vs. Metrodin) in in vitro fertilization. Hum Reprod 1995 ; 10 : 2534 –40.
2. Devroy P, Tournaye H, Van Steirteghem A, Hendrix P, Out HJ. The use of a 100 IU starting dose recombinant follicle stimulating hormone(Puregon) in in vitro fertilization. Hum Reprod 1998 ; 13 : 565 –6.
  3. De Placido G, Alviggi C, Mollo A, Strina I, Varricchio MT, Molis M. Recombinant follicle stimulating hormone is effective in poor responders to highly purified follicle stimulating hormone. Hum Reprod 2000 ; 1 : 17 –20.
  4. Out HJ, Mannerts BMJL, Driessen SGAJ, Coeling Bennick HJT. Recombinant follicle stimulating hormone(rFSH ; Puregon) in assisted reproduction : more oocytes, more pregnancies. Results from five comparative studies. Hum Reprod Update 1996 ; 2 : 162 –71.
  5. Recombinant Human FSH Study Group. Clinical assessment of recombinant follicle stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril 1995 ; 63 : 77 –86.
  6. Bergh C, Howels CM, Borg K, Hamberger L, Josefsson B, Nilsson L, et al. Recombinant follicle stimulating hormone(rFSH ; Gonal – F) : results of a randomised comparative study in women undergoing assisted reproductive technique. Hum Reprod 1997 ; 12 : 2133 –9.
  7. Vilska S, Tiitinen A, Hyden – Granskog C, Hovatta O. Elective transfer of one embryo results in acceptable pregnancy rate and eliminates the risk of multiple birth. Hum Reprod 1999 ; 14 : 2391 –4.
  8. Moilanen J, Tulppala M, Reima I. Fertilization, embryo quality and cryosurvival in IVF and ICSI cycles. J Assist Reprod Genet 1999 ; 16 : 17 –23.
  9. Daya S, Gunby J, Hughes EG, Collins JA, Sagle MA. Follicle stimulating hormone versus human menopausal gonadotropin for in vitro fertilization : a meta – analysis. Fertil

- Steril 1995 ; 64 : 347 –54.
10. Loumaye E, Martineau I, Piazzzi A. Clinical assessment of human gonadotrophins produced by recombinant DNA technology. Hum Reprod 1996 ; 11 : 95 –107.
  11. Harlin J, Csemiczky G, Wrambsy H, Fried G. Recombinant follicle stimulating hormone in in vitro fertilization treatment : clinical experience with follitropin alpha and follitropin beta. Hum Reprod 2000 ; 15 : 239 –44.
  12. Albano C, Felberbaum RE, Smitz J. Ovarian stimulation with HMG : results of a prospective randomized phase III European study comparing the LHRH antagonist cetorelix and the LHRH agonist buserelin. European Cetorelix Study Group. Hum Reprod 2000 ; 15 : 526 –31.
  13. Olivennes F, Belaisch – Allart J, Empeiraire JC. Prospective, randomized, controlled study of in vitro fertilization – embryo transfer with a single dose of a LHRH antagonist(cetorelix) or a depot formula of an LHRH agonist(triptorelin). Fertil Steril 2000 ; 73 : 314 –20.
  14. Diedrich K, Diedrich C, Santos E. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin releasing hormone antagonist Cetorelix during ovarian stimulation. Hum Reprod 1994 ; 9 : 788 –91.
  15. Albano C, Smitz J, Camus M. Comparison of different doses of gonadotropin releasing hormone antagonist Cetorelix during controlled ovarian hyperstimulation. Fertil Steril 1997 ; 67 : 917 –22.
  16. Olivennes F, Fanchin R, Bouchard P. Scheduled administration of a gonadotropin releasing hormone antagonist(Cetorelix) on day 8 of in vitro fertilization cycles. : a pilot study. Hum Reprod 1995 ; 10 : 1382 –6.
  17. Albano C, Grimbizis G, Smitz J. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin releasing hormone antagonist Cetorelix. Fertil Steril 1998 ; 70 : 357 –9.
  18. Hernandez ER. Embryo implantation : the Rubicon for GnRH

- antagonists. Hum Reprod 2000 ; 15 : 1211 –6.
19. Felberbaum RE, Reissmann T, Kupker W. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists(Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol 1995 ; 61 : 151 –5.
  20. Olivennes F, Fanchin R, Bouchard P. Triggering of ovulation by a gonadotropin releasing hormone(GnRH) antagonist in patients pretreated with a GnRH antagonist. Fertil Steril 1996 ; 66 : 151 –3.